clinical trial · NCT07691762
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·phase3·not yet recruiting·n = 690
Hepatocellular CarcinomaSHR-8068+ Adebrelimab+ BevacizumabSHR-8068 Placebo+ Adebrelimab Placebo+ Bevacizumab PlaceboSHR-8068 Placebo +Adebrelimab+ Bevacizumab
brief summary
This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma. Participants will continue treatment until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.
started
Jul 1, 2026
primary completion
Apr 1, 2031
completion
Apr 1, 2031
last updated
Jul 9, 2026
official title
A Phase III, Randomized, Double-blind, Multicenter Study of SHR-8068 and Adebrelimab Plus Bevacizumab in Combination With TACE in Participants With Incurable Hepatocellular Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol